Dr. Frans Van Andel

Dr Frans Van Andel



Region Covered

BeNeLux & EMEA



Frans is a board director for  PPi Healthcare Consulting.

He is PPi HC country director for BeNeLux markets as well as Eastern Europe, Middle East and Africa.

He brings more than 25 years of experience in market access issues involving pharmaceuticals and medical devices with past experience in the pharmaceutical industry, CRO’s, academia and WHO. In addition to market access services, Frans’ team provides health economic modelling, cost-effectiveness and quality of life analyses on a global basis.

Frans has degrees in health economics (Universities of Groningen and Utrecht) and public health (Harvard, USA). He owns a PhD in pharmaceutical economics (Erasmus University Rotterdam).



With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project. Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!

Thomas W. MacAllister JD, PhD,Vice President of R&D and General Counsel, Remedy Pharmaceuticals